Shira Markowitz, Jonathan Rosenblum, Leib Litman and Hrishikesh Gadagkar
The Authors evaluate the effect of a Surface Acoustic Wave device (NanoVibronix Inc. Elmsford, NY, USA) on the symptomatology of Trigeminal Neuralgia. 59 subjects completed the trial. This was a double-blinded randomized control trial that measured subjective pain relief as measured by VAS and subjective results measured by the reduction of use of breakthrough narcotic medications. There was a significant reduction in subjective pain reported as well as in the number of uses of breakthrough opioid medications. There was trending towards an increase in quality of life scores. The investigational device had no adverse events or complications and was deemed both safe and efficacious.
Recent Comments